Matthew Perry's Doctor Admits to Ketamine Smuggling

The Legal Consequences of Ketamine Distribution in the Death of Matthew Perry

In a significant legal development, one of two physicians charged in connection with the death of "Friends" star Matthew Perry from a ketamine overdose in October 2023 has pleaded guilty to federal charges. Salvador Plasencia, 42, from Santa Monica, entered his plea before a federal judge to four counts of distributing ketamine. His sentencing is scheduled for December 3, where he could face up to 40 years in prison and a fine of at least $2 million, according to his plea agreement.

Plasencia remains free on bond and has indicated through his lawyers that he intends to surrender his medical license within the next 30 to 45 days. This case is part of a broader investigation involving five defendants, all of whom were charged in relation to Perry’s death. Four individuals, including Plasencia, have already pleaded guilty and are awaiting sentencing, while the last defendant, alleged ketamine dealer Jasveen Sangha, is set to go to trial next month.

The Role of Ketamine in Perry’s Death

According to federal prosecutors, in late September 2023, Plasencia learned that Perry, who had a documented history of drug addiction, was interested in obtaining ketamine. Ketamine is a powerful anesthetic that requires careful administration by a healthcare professional due to its potential risks. Instead of adhering to proper medical protocols, Plasencia sought out ketamine for Perry through unconventional means.

Plasencia contacted Mark Chavez, a San Diego physician who previously operated a ketamine clinic, to obtain the drug. In text messages, Plasencia discussed pricing with Chavez, making derogatory remarks about Perry, such as “I wonder how much this moron will pay” and “Let’s find out.” Over the course of September and October 2023, Plasencia distributed ketamine to Perry and his assistant, Kenneth Iwamasa, on at least seven occasions without a legitimate medical purpose.

Chavez, in turn, sold Plasencia ketamine lozenges obtained through fraudulent prescriptions and lied to distributors to acquire more ketamine for resale. Prosecutors noted that Perry was paying $2,000 per vial, while his dealers paid only $12 per vial. This discrepancy highlights the exploitative nature of the distribution network.

The Broader Implications of the Case

Perry's struggles with addiction were well-documented in his 2022 memoir, “Friends, Lovers, and the Big Terrible Thing,” where he described multiple detox attempts. He was found dead on October 28, 2023, in a hot tub behind his home in Pacific Palisades due to a fatal ketamine overdose. At the time of his death, he was 54 years old.

The case led to the charging of five defendants in August 2024. Mark Chavez, 54, pleaded guilty in October 2024 to conspiring to distribute ketamine and is expected to be sentenced in September. Kenneth Iwamasa, 59, admitted to injecting Perry with ketamine without medical training and is set for sentencing in November.

Jasveen Sangha, dubbed the “Ketamine Queen” by prosecutors, faces trial next month on charges related to conspiracy, drug distribution, and possession of methamphetamine. Erik Fleming, 54, pleaded guilty to distributing ketamine that resulted in Perry’s death and is set for sentencing in November.

The Final Days and Aftermath

According to court documents, Iwamasa used syringes and instructions provided by Plasencia to inject Perry with ketamine on multiple occasions, including the day he died. Despite being aware that Perry’s addiction was worsening, Plasencia continued to supply him with the drug.

After Perry’s death was reported in the media, Sangha allegedly instructed Fleming to delete all messages, indicating an attempt to cover up their involvement. This case underscores the dangers of unregulated drug distribution and the tragic consequences of prioritizing profit over patient safety.

As the legal proceedings continue, the case serves as a stark reminder of the ongoing challenges surrounding substance abuse and the need for accountability in the medical and pharmaceutical industries.